Ifebemtinib is an orally bioavailable inhibitor of the non-receptor, cytoplasmic tyrosine kinase protein tyrosine kinase 2 (FAK: PTK2) with potential antineoplastic activity. It targets and inhibits PTK2 in an adenosine triphosphate (ATP)-competitive manner, preventing PTK2-mediated downstream signaling and inhibiting migration, proliferation, invasion, and survival in PTK2-overexpressing tumor cells.
- Orally bioavailable inhibitor of FAK1/PTK2
- Targets and inhibits PTK2 in an ATP-competitive manner
- Prevents PTK2-mediated downstream signaling
- Inhibits migration, proliferation, invasion, and survival in PTK2-overexpressing tumor cells
- Stable under recommended storage conditions